<DOC>
	<DOCNO>NCT00052195</DOCNO>
	<brief_summary>A significant number HIV infect patient Africa also disseminate tuberculosis ( infection throughout multiple organ ) . This type tuberculosis significant cause mortality patient . The purpose study evaluate safety effectiveness vaccine design prevent disseminate tuberculosis .</brief_summary>
	<brief_title>Investigational Vaccine Prevention Disseminated Tuberculosis HIV Infected People</brief_title>
	<detailed_description>Disseminated infection Mycobacterium tuberculosis ( dMTB ) document 10 % 25 % patient HIV infection Africa . Unlike pulmonary tuberculosis ( pMTB ) , case dMTB recognize death ensues rapidly . Therefore , dMTB may important cause HIV-associated mortality pMTB develop country . Mycobacterium vaccae ( MV ) investigational vaccine prepare heat inactivation nontuberculous mycobacteria . MV immunization may reduce risk HIV-associated dMTB . The purpose study define risk factor HIV-associated dMTB ass safety effectiveness MV vaccine prevention HIV-associated pulmonary disseminate tuberculosis . HIV positive patient prior BCG immunization HIV negative control enter 5-year study Tanzania . Participants randomize receive 5-dose series MV placebo 12 month , repeat skin test Month 14 . Baseline evaluation include medical history , chest x-ray , skin test purify protein derivative ( PPD ) , blood test evaluate interferon-gamma production . Participants PPD reaction great equal 5 mm receive 6 month prophylaxis isoniazid . Participants follow every 3 month 3 5 year assess new pMTB ( microbiologic clinical diagnosis ) dMTB ( microbiologic diagnosis ) . Potential risk factor dMTB also assess .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>HIV infection CD4 count 200 cells/mm3 BCG scar Active tuberculosis . Patients defer study enrollment show sign active disease . Serious underlying disease ( e.g. , congestive heart failure , advanced cancer ) Life expectancy le 2 year Pregnancy . Women pregnant may eligible study give birth .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Mycobacterium vaccae</keyword>
	<keyword>BCG</keyword>
	<keyword>Disseminated tuberculosis</keyword>
	<keyword>SRL-172</keyword>
	<keyword>DAR-901</keyword>
</DOC>